Posted by Michael Wonder on 10 Jul 2019
ICER's final report on peanut allergy treatments: clinical evidence does not yet demonstrate that long-term benefits of desensitisation outweigh short-term risks
10 July 2019 - Independent appraisal committee highlights importance of non-clinical benefits and contextual considerations when evaluating AR101 and Viaskin Peanut.
ICER today released a final evidence report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of two investigational technologies that treat children with peanut allergy by building their immune tolerance to peanuts.
The report evaluates Viaskin Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics), as well as non-commercialised oral immunotherapy (OIT). An FDA decision on AR101 is expected by January 2020. A biologics license application for Viaskin Peanut was withdrawn in December 2018, but another is expected to be resubmitted later this year.
